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esponsibility of InstAbstract The objective of the study was to prepare solid dispersions containing a thermally unstable drug by
hot-melt extrusion (HME). Carbamazepine (CBZ) was selected as model drug and combinations of Kollidon
VA64 (VA64), Soluplus (SOL) and Eudragit EPO (EPO) were utilized as carriers. Preformulation was conducted
to identify the suitability of polymer combinations based on solubility parameters, differential scanning calorimetry
(DSC), hot stage microscopy and thermogravimetric analysis. Physicochemical properties of solid dispersions were
determined by DSC, X-ray diffraction, fourier transform infrared spectroscopy, dissolution and accelerated stability
testing. The results show that drug-polymer miscibility at temperatures below the melting point (Tm) of CBZ was
improved by combining EPO with VA64 or SOL. With 30% drug loading in a solid dispersion in SOL:EPO (1:1,
w/w), CBZ was mainly present in an amorphous form accompanied by a small amount of a microcrystalline form.
The dissolution rate of the solid dispersion was signiﬁcantly increased (approximately 90% within 5 min)
compared to either the pure drug (approximately 85% within 60 min) or the corresponding physical mixture
(approximately 80% within 60 min) before and after storage. The solid dispersion in SOL:EPO (1:1, w/w) was
relatively stable at 40 1C/75% RH under CBZ tablet packaging conditions for at least 3 months. In conclusion,
polymer combinations that improve drug-polymer miscibility at an HME processing temperature below the Tm of
a drug appear to be beneﬁcial in the preparation of solid dispersions containing thermally unstable drugs.
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Association. Production and hosting by Elsevier B.V. All rights reserved.dica, Chinese Academy of Medical Sc
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Figure 1 Molecular structures of carbamazepine and polymers.
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In drug discovery, the number of active pharmaceutical ingredients
(APIs) with poor water-solubility continues to increase with over
50% of APIs now belonging to Class II of the Biopharmaceutics
Classiﬁcation System (BCS). Because the solubility and/or dis-
solution rate is the rate limiting step to oral absorption for BCS
Class II drugs, improvement in either or both properties is
considered a key factor for enhancing their bioavailability1.
Structural modiﬁcations such as formation of a salt, prodrug2 or
different polymorph3 and pharmaceutical technologies such as
micronization4, formation of solid dispersions5 or inclusion
compounds6 have been widely used to enhance the solubility
and/or dissolution rate. Among these methods, application of solid
dispersion technology is considered to be one of the most
attractive options7,8 involving either hot-melt extrusion (HME)9,
solvent co-precipitation10, spray drying11 or grinding12.
In recent years, HME has received widespread attention from
the pharmaceutical industry for the production of oral solid
dispersions. HME has various advantages over traditional indus-
trial methods including avoidance of solvents and applicability to
drugs and adjutants for which a suitable solvent is lacking. It
enables sufﬁcient mixing in a short residence time and can be used
to produce formulations with controlled, sustained or targeted
release13,14. Selected polymers can also serve to mask the bitter
taste of certain APIs15,16. In addition, HME is a continuous and
controllable process that can be scaled up to a commercially
meaningful level17. However, HME is limited in its application to
thermally unstable drugs that degrade at the high temperatures and
shear forces employed in the extrusion process18. This paper
reports a technique to avoid this limitation.
For thermally stable APIs, HME can be conducted at a
temperature above their melting point (Tm) that ensures complete
conversion of a crystalline to an amorphous form. Such higher
temperatures serve to reduce the viscosity of the drug-polymer
system to facilitate extrusion. It is also possible to obtain solid
dispersions using an extrusion temperature below the Tm of the
API by the input of adequate shear forces and selecting a polymer
capable of solubilizing the API and providing low viscosity at
processing temperatures19–21. However, this is not possible for all
drug-polymer combinations since it depends on an interaction
between the two components that is very sensitive to their
physicochemical properties. The screening of polymers for good
miscibility with drug has been attempted by many researchers but
few publications have reported improvements in poor miscibility
systems.
In the preparation of solid dispersions by HME, single polymers
have been generally used as carriers despite the fact that some
drugs are only poorly soluble in single polymers. Previous studies
have reported that using combinations of polymers can provide a
synergistic advantage that includes avoiding unfavorable charac-
teristics of a melt extruded ﬁlm22, modifying the dissolution
proﬁle23 and enhancing the physical stability and oral absorption
of solid dispersions24. To further pursue this research, we have
investigated the potential miscibility improvement of polymer
combinations used to prepare a solid dispersion of the thermally
unstable, BCS Class II drug, carbamazepine (CBZ) by HME and
combinations of Eudragit EPO (EPO) with either Kollidon VA64
(VA64) or Soluplus (SOL). CBZ exists as at least four anhydrous
polymorphs and several solvates among which the anhydrous form
III is the only form used in marketed products used to treat
epilepsy and trigeminal neuralgia25. The big challenge encounteredin preparing a solid dispersion of CBZ by HME is that the drug
substance degrades at its Tm
26.
In this study, a solubility parameter was utilized to give a
preliminarily indication of the interaction between the drug and
polymers. This was followed by thermogravimetric analysis
(TGA), differential scanning calorimetry (DSC) and hot stage
microscopy (HSM) to assess the thermal stability of materials and
drug-polymer miscibility. Solid dispersions of CBZ embedded in
single polymers and polymer combinations were then prepared by
HME and examined by DSC, X-ray diffraction (XRD), fourier
transform infrared spectroscopy (FTIR) and high-performance
liquid chromatography (HPLC). In this way, the miscibility of
polymer combinations and physicochemical properties of corre-
sponding solid dispersions were fully evaluated.2. Materials and methods
2.1. Materials
CBZ was purchased from Zhejiang Jiuzhou Pharmaceutical Co.,
Ltd. (Zhejiang, China). Kollidon VA64 and Soluplus were donated
by BASF (Shanghai, China). Eudragit EPO was kindly supplied
by Evonik (Shanghai, China). All other chemicals were of
analytical or chromatographic grade and used as received. The
structures are shown in Fig. 1.
2.2. CBZ-polymer miscibility analysis
2.2.1. Calculation of solubility parameters (δ) and glass
transition temperature (Tg)
As an indicator of the drug-polymer miscibility, values of δ were
calculated using the Hoftyzer and van Krevelen group contribution
method27 described by Eq. (1).
δ2 ¼ δd2 þ δp2 þ δh2 ð1Þ
where
δd ¼
∑Fdi
V
; δp ¼
ð∑Fpi2Þ1=2
V
; δh ¼
∑Fhi
V
 1=2
here i is the groups within the molecule, δ is the total solubility
parameter, δd is the contribution from dispersion forces, δp is the
contribution from polar interactions, δh is the contribution of
hydrogen bonding, Fdi is the molar attraction constant due to molar
dispersion forces, Fpi is the molar attraction constant due to molar
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the molar volume.
The solubility parameters of polymer combinations were
calculated using Eq. (2) 28
δ1;2 ¼ V ′1δ1 þ V ′2δ2 ð2Þ
where V′ is the volume fraction of each compound.
The glass transition temperature (Tg) of polymer combinations
was calculated using the Gordon–Taylor equation, Eq. (3)29
Tg12 ¼
ðW1Tg1 þ KW2Tg2Þ
ðW1 þ KW2Þ
ð3Þ
where
K ¼ Tg1ρ1
Tg2ρ2
here ρ is the density and W is the weight fraction of each
compound. The Tg and ρ values of the three polymers reported
in the literature24–26,29–33 were used in the calculation.2.2.2. Miscibility analysis by modulated temperature DSC (MT-
DSC)
This was carried out using a NETZSCHS DSC 204 (NETZSCH
group, Germany). Accurately weighed samples (2–3 mg) were
placed in sealed aluminum pans and a heat-cool-heat cycle applied
involving heating from 30 to 220 1C at 10 1C/min then rapidly
cooling to 30 1C and then reheating to 220 1C at 10 1C/min.2.2.3. Miscibility observation by HSM
HSM was conducted using a Linkham DSC600 as hot stage
(Linkham Scientiﬁc Instruments Co., Ltd., England) under a Leica
DMPL polarizing optical microscope (Leica Microsystems Wetzar
Gmbh, Germany). The phase transition during the heat-cool-heat
process was observed and images captured under polarizing light
for further analyses.
Samples were placed on open glass slides, ﬁxed on the hot stage
and heated from 30 to 190 1C at 10 1C/min. The temperature was
maintained at 190 1C for 15 min after which samples were rapidly
cooled to 30 1C and then reheated to 190 1C at 10 1C/min.2.3. Preparation and characterization of solid dispersions
2.3.1. Preparation by HME
Prior to HME, TGA was used to evaluate the thermal stability of
the drug and polymers. Samples were placed in open aluminium
pans of a NETZSCHS DG 209 (NETZSCH group, Germany) and
heated from room temperature to 250 1C at 10 1C/min under a
nitrogen atmosphere.
HME was performed using a co-rotating (diameter 5–14 mm)
twin screw HAAKE MiniCTW extruder (Thermo Scientiﬁc,
Germany) equipped with a 2 mm round opening die. Considering
the high content of CBZ tablets (100 or 200 mg per tablet), all
extrudates were prepared with a high drug loading of 30%.
Drug and polymers were accurately weighed, mixed and then
continuously fed into the extruder operating at a screw speed of
30 rpm and an extrusion temperature of 185 1C or 165 1C which is
below the Tm of CBZ. Extrudates were collected as strands, air-
cooled and then milled in a mortar until the resulting powder
passed through an 80-mesh sieve.2.3.2. Characterization of solid dispersions
DSC was performed as in Section 2.2.2 except that only a heat
cycle from 30 to 220 1C at 10 1C/min was performed under a
nitrogen atmosphere.
XRD was carried out at room temperature using a D/max
2500VL/PC powder X-ray diffractometer (Rigaku, Japan) operat-
ing at 40 kV and 40 mA to determine the presence of crystals in
extrudates. Samples were scanned over a 2θ range of 3–401 with a
step size of 0.021 and a step time of 0.3 s.
FTIR was performed in the 4000–400 cm−1 region using a
983G FTIR spectrometer (Perkin Elmer, USA) operating at 4 cm−1
resolution and 64 scans per spectrum. Powder samples were mixed
with KBr (1%, w/w), compressed into pellets and scanned
immediately.2.4. Solubilization and stability studies
2.4.1. Dissolution testing
This was performed according to Dissolution Test Method 2 as
described in the paragraph on CBZ tablets in the Chinese
Pharmacopoeia (2010)34 using a ZRS-8G dissolution tester
(Tianda Tianfa Technology Co., Ltd., China) with a rotation speed
of 150 rpm. Samples containing the equivalent of 100 mg CBZ
were accurately weighed and added to the dissolution vessel
containing 1 L 0.065 M HCl. Aliquots (10 mL) were taken at
various times and immediately ﬁltered through a 0.45 μm ﬁlter.
Filtrates were diluted 1:10 with fresh dissolution medium and then
analyzed for CBZ by measuring absorbance at 285 nm using a
Rayleigh UV 9600 spectrophotometer (Beijing Ruili Analysis
Equipment Co., Ltd., China). Each study was performed in
triplicate.2.4.2. HPLC analysis
CBZ and related substances in extrudates were determined using a
Shimadzu LC-2010C HT HPLC system (Shimadzu Corporation,
Japan) with an Inertsils ODS-SP C18 column (150 mm 4.6 mm,
5 μm; GL Science, USA) and a mobile phase of methanol:water
(55:45, v/v) delivered at 1.0 mL/min. The injection volume was
20 μL and detection was at 285 nm for CBZ and at 230 nm for
related substances.2.4.3. Accelerated stability testing
Extrudates were sealed in bottles protected from light and stored at
40 1C/75% RH for 3 months (storage conditions for CBZ tablets).
Any recrystallization of CBZ in the products was then determined
by XRD. The content of CBZ and related substances and
dissolution of the products were also determined.2.4.4. Hygroscopicity
Hygroscopicity of CBZ, polymers and extrudates was determined
gravimetrically. Accurately weighed samples (approximately 1 g)
were placed in chambers under controlled relative humidity (RH)
and weighed after storage for 7 days at room temperature. RH in
chambers was produced by equilibrating with saturated salt
solutions as follows: K2CO3 44% RH; NaBr 60% RH; NaCl
75% RH; and KNO3 92.5% RH at room temperature.
Table 1 Values of solubility parameters (δ), glass transition temperatures (Tg) and their differences from CBZ values (Δδ and ΔTg) for
CBZ and polymers.
Sample δd (MPa
1/2) δp (MPa
1/2) δh (MPa
1/2) δ (MPa1/2) Δδ (MPa1/2) ρliterature (g/cm3) Tg literature (1C) ΔTg (1C)
CBZ 22.0 7.0 9.6 25.0 – 1.338 59 –
VA64 19.4 9.7 9.6 23.7 1.3 1.167 101 42
SOL 18.5 10.9 10.2 22.1 2.9 0.99 71 12
EPO 17.3 5.4 8.8 20.2 4.8 1.03 48 11
VA64:EPO (1:2, w/w) – – – 22.1 2.9 – 57.0a 2.0
SOL:EPO (1:1, w/w) – – – 29.9 4.9 – 57.5a 1.5
aCalculated by Eq. (3).
Figure 2 MT-DSC thermograms of (a) CBZ; (b) and (c) physical
mixtures of CBZ and VA64:EPO (1:2, w/w); (d) and (e) physical
mixtures of CBZ and SOL:EPO (1:1, w/w); (b) and (d) the ﬁrst heating
process; (c) and (e) the second heating process.
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3.1. Miscibility analysis based on δ and Tg values
It is generally believed that favorable interactions and a uniform
phase will result when the difference in δ values (Δδ) between two
components is less than 7 MPa1/2, while unfavorable interactions
and phase separation will result when Δδ410 MPa1/2 35. The
calculated solubility parameters are presented in Table 1. The δs of
CBZ, VA64, SOL and EPO are similar and are close to the
reported data24,33,36,37. The Δδs values between CBZ and the three
polymers were in the range 1.68–4.84 MPa1/2, being less than
7 MPa1/2 indicates likely miscibility. However, the combinations
of EPO with VA64 or SOL appear to increase the Δδs between
CBZ and polymer mixtures which does not imply miscibility
improvement.
The Tg values of the three amorphous polymers VA64, SOL
and EPO were 101, 71 and 48 1C, respectively. The ΔTg values
between CBZ and the three polymers were 42, 12 and 11 1C,
respectively. Interestingly, the Tg values of polymer combinations
are very close to that of CBZ.
Since the Tg value indicates a temperature above which polymer
chains become ﬂexible, more interactions are expected to occur in
the heating process if components have similar Tg values. After
comparing a series of ratios according to the dispersion state of
CBZ and the moldability of extrudates, VA64:EPO (1:2, w/w) and
SOL:EPO (1:1, w/w) were ﬁnally chosen as the most promising
carriers. The results suggest that ΔTg may be useful in predicting
miscibility in the thermal process.3.2. CBZ-polymer miscibility under thermal processing
conditions
3.2.1. MT-DSC studies
MT-DSC studies were performed to identify whether an amor-
phous solid dispersion of CBZ was formed by HME. Compared to
the sharp melting peak of pure CBZ, the endothermic peaks in
physical mixtures broadened during the ﬁrst heating cycle and then
disappeared in the second heating cycle. This is caused by gradual
dissolution of the crystalline drug in the molten polymers and
complete conversion to the amorphous state during the DSC
heating process (Fig. 2).3.2.2. HSM studies
HSM can provide visual evidence to conﬁrm the results of MT-
DSC. Images taken under polarizing light are shown in Fig. 3.
Pure CBZ in form III (P-monoclinic crystal) began to melt andtransform to form I (needle crystal) at approximately 165 1C and
subsequently underwent complete melting at 190 1C. During the
rapid cooling process, recrystallization to needle crystals which
quickly covered the whole ﬁeld of view occurred. For both
physical mixtures, extensive solubilization of CBZ in molten
VA64:EPO (1:2, w/w) and SOL:EPO (1:1, w/w) occurred at
approximately 165 1C and was complete at 190 1C. Upon rapid
cooling and reheating, the crystals of CBZ were no longer
observed, indicating miscibility of CBZ and polymer combinations
and the formation of amorphous CBZ after the heat-cool cycle.
The visual observations correlated well with the results of MT-
DSC and provide strong evidence for the formation of a solid
dispersion containing amorphous CBZ by HME.
It was noticed that CBZ crystals were almost melted and
transformed to the amorphous state in extrudates produced at
165 1C. For physical mixtures of the same formulations, however,
CBZ crystals were not dissolved completely when the temperature
was maintained at 165 1C for 15 min which is obviously longer than
the residence time of the HME process. This clearly demonstrates that
the dissolution of CBZ in molten polymers is facilitated by the input
of adequate shear forces in the HME process.3.3. Stability of CBZ and formation of solid dispersions
3.3.1. The effect of processing temperatures
TGA was used to evaluate the thermal stability of materials during
the heating process. As illustrated in Fig. 4A, VA64, SOL and
Figure 3 HSM images of phase transition.
Polymer combination of solid dispersions of carbamazepine 267EPO were thermally stable up to 230, 220 and 200 1C, respec-
tively, although 2.81% and 2.01% free water was lost at
temperatures below 100 1C for VA64 and SOL, respectively.
Mass loss or degradation of CBZ was observed at its Tm (190 1C)
indicating the extrusion temperature should be set below 190 1C.
The thermal stability of CBZ in different formulations during the
HME process and the appearance of corresponding extrudates are
presented in Table 2.Formulations 1–6 consist of CBZ and single polymers (VA64,
SOL or EPO). Initially, HME was attempted at 185 1C but obvious
browning of extrudates was evident accompanied by respectively
18.5%, 11.6% and 9.4% drug degradation. It has been reported
that, in the HME process, the decomposition of thermally unstable
substances may occur at temperatures much lower than that
predicted by TGA of the pure drug because the crystalline drug
dissolves in the molten polymer and is gradually transformed to
Figure 4 TGA of (A) CBZ and polymers and (B) physical mixtures (PM) of formulations 7 and 8.
Table 2 Formulations, CBZ content remaining after HME and appearance and moldability of extrudates.
Formulation Polymer Process temp. (1C) CBZ content (%) Appearance Moldability
1 VA64 185 81.5 Transparent GOOD
2 VA64 165 ND CBZ crystals present GOOD
3 SOL 185 88.4 Transparent GOOD
4 SOL 165 ND CBZ crystals present GOOD
5 EPO 185 90.6 Opaque POOR
6 EPO 165 ND Opaque POOR
7 VA64:EPO (1:2, w/w) 165 98.6 Semi-translucent GOOD
8 SOL:EPO (1:1, w/w) 165 96.7 Semi-translucent GOOD
ND: not determined.
J. Liu et al.268the amorphous state. In addition, the intensive mixing and high
screw speed also probably contribute to decreasing the temperature
of onset of degradation38. In order to conﬁrm this, TGA was
conducted on physical mixtures corresponding to formulations 7
and 8 and degradation observed at approximately 172 1C and
175 1C, respectively, which are much lower than the degradation
temperature of pure CBZ (Fig. 4B).
Based on these observations, HME was carried out at 165 1C.
For formulations 2 and 4, CBZ was not completely dissolved in
the single polymers (VA64 or SOL) as small amounts of CBZ
particles were observed in the extrudates. This phenomenon
indicates the poor miscibility of CBZ and VA64 (SOL) which is
assumed to result from the high melt viscosity of the polymers
under such HME conditions. We attempted to facilitate the
dissolution rate of CBZ by speeding up the extruder screw speed
or extending the residence time but signiﬁcant degradation
occurred (data not shown). For formulations 5 and 6, extrudates
could not be collected conveniently possibly due to the low Tg
(48 1C) of EPO which caused very low melt viscosity and poor
moldability at 185 1C.
3.3.2. The effect of polymer combinations on formation of solid
dispersions and moldability of extrudates
To conﬁrm the miscibility improvement of polymer combinations,
formulations 7 and 8, consisting of CBZ and polymer combina-
tions VA64/EPO or SOL/EPO, were extruded at 165 1C. Semi-
translucent and homogeneous extrudates were obtained with only
slight degradation of CBZ. The greater miscibility of these polymer
combinations may be due to decreases in the viscosity of the molten
systems. As the torque value is proportional to viscosity, the impact
of EPO on the torque values of molten polymer combinations was
investigated. Incorporation of EPO was found to produce a signiﬁcantplasticizing effect on the viscosity of VA64 and SOL as indicated by
large reductions in torque values (Fig. 5).
The plasticizing effect of EPO on the viscosity of a molten
polymer combination leads to an improvement in the mixing
homogeneity within the chamber and a decrease in the thickness of
the mass transfer boundary layer around drug particles, thus
increasing the dissolution rate of CBZ in the molten polymer. A
similar effect of viscosity on drug-polymer miscibility had been
previously reported38. Suzuki and Sunada39 used DSC to show
that high viscosity limits the miscibility of nifedipine and HPMC.
Fu et al.32 also reported that the high viscosity of VA64 under
extrusion at 120–130 1C prevented uniform mixing with other
ingredients due to its high softening point (approximately 180 1C)
and resulted in a lower drug release.
The results of these studies suggest solubility parameters are
limited in their ability to predict miscibility of molten systems as
the thermal properties of polymers such as melt viscosity are not
taken into account. Furthermore, the dissolution capability of a
drug in a molten polymer could also be underestimated even when
thermal factors are considered. As indicated in the HSM mis-
cibility analysis, mixing homogeneity was limited due to the
absence of any shear forces. Hence it is reasonable to suggest that
the thermal properties of polymers such as melt viscosity and Tg
should be combined with solubility parameters to improve mis-
cibility prediction.
Although the dissolution of CBZ should be improved by
decreasing the melt viscosity of the carrier, the moldability of
resulting extrudates will suffer if the viscosity is decreased too
much. Thus, taking into account both the dispersion state of CBZ
and the moldability of extrudates, extrudates made from combina-
tions of EPO and VA64 (SOL) with a ﬁxed CBZ loading of 30%
were evaluated. VA64:EPO (1:2, w/w) and SOL:EPO (1:1, w/w)
Figure 5 Torque values of (A) VA64/EPO combinations and (B) SOL/EPO combinations at different temperatures.
Figure 6 DSC curves of (A) CBZ, polymers and physical mixtures (PM) and extrudates (Ext) from formulation 7 and (B) physical mixtures
(PM) of formulation 8 and extrudates (Ext) from SOL:EPO (1:1, w/w) with different drug loading.
Figure 7 XRD proﬁles of CBZ, polymers, physical mixtures (PM)
and extrudates (Ext) from formulations 7 and 8.
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the physicochemical properties, dissolution and stability of corre-
sponding solid dispersions were fully determined.
3.4. Physical characterization
3.4.1. DSC proﬁles
DSC proﬁles of CBZ, polymers, extrudates and corresponding
physical mixtures of formulations 7 and 8 are shown in Fig. 6A. In
the thermogram of CBZ, the small endothermic peak at 169.8 1C
followed by a sharp endothermic peak at 190.4 1C suggest a
polymorphic transformation of CBZ. These two endothermic
peaks were attributed to the melting of the original form III, and
the melt-recrystallized form I of CBZ, respectively40.
Although peak areas were small, endothermic peaks at approxi-
mately 150–160 1C corresponding to the crystalline drug were still
present in the DSC thermograms of extrudates indicating that most
CBZ was dispersed in an amorphous state with a small amount
remaining in a crystalline state. By comparing the endothermic
enthalpy of extrudates with that of pure CBZ, it was calculated that
approximately 8.2% and 7.7% undissolved drug crystals are
present in the extrudates from formulations 7 and 8, respectively.
Since incomplete dissolution of drug is usually due to over-
loading, solid dispersions with different drug loading were
prepared in SOL:EPO (1:1, w/w) and the corresponding DSC
curves analyzed. As shown in Fig. 6B, the enthalpy and onset
temperature of drug endothermic peaks gradually decreased and
ﬁnally disappeared as drug loading decreased from 30% to 15%. This
suggests that the polymer combination was saturated with CBZ at the
30% loading. Generally, complete transformation to the amorphousstate results in better solubilization but, considering the high CBZ
content of tablets (100 mg or 200 mg per tablet), a high drug loading
may be required in preparing such tablets by HME if drug stability
can be maintained over the desired shelf life.3.4.2. X-ray diffraction
XRD proﬁles, shown in Fig. 7, reveal no evidence of CBZ crystals
in either extrudate. This inconsistency probably results from the
lower sensitivity of XRD compared to DSC to detect small-sized
crystals even when their concentration in the sample is above the
limit of detection41. Since micron sized crystals were also shown
Figure 8 FTIR spectra of CBZ, polymers, physical mixtures (PM)
and extrudates (Ext) from formulations 7 and 8. Figure 9 Dissolution proﬁles of CBZ, physical mixtures (PM) and
extrudates (Ext) from formulations 7 and 8 (n¼3).
J. Liu et al.270to be present in extrudates by HSM, It can be concluded that CBZ
was mainly present in an amorphous form accompanied by a small
amount of a microcrystalline form.3.4.3. FTIR characterization
Possible interactions between drug and polymers in extrudates
were investigated by FTIR. As shown in Fig. 8, CBZ form III has
characteristic peaks (cm−1) at 3465 (free anti-NH stretching), 3157
(hydrogen bonded syn-NH stretching), 1677 (amide C=O stretch-
ing), 1605 and 1594 (aromatic and C=C stretching)42. In CBZ, the
NH2 and C=O groups are capable of forming hydrogen bonds with
polymers.
Polymer peaks indicative of an interaction with drug include the
hydrogen bonding acceptor C=O stretching and the hydrogen
bond donor O–H stretching. The relevant peaks are as follows:
VA64—the vinyl pyrrolidone monomer C=O at 1678 cm−1 and
the vinyl acetate monomer C=O at 1740 cm−1; EPO—the ester
C=O at 1731 cm−1; SOL—the vinyl acetate monomer ester C=O
at 1741 cm−1, the vinyl caprolactam monomer C=O at 1643 cm−1
and the O–H group at 3464 cm−1. Any changes in the wave
numbers or shapes of these peaks reﬂect an interaction between
CBZ and the respective polymers.
The FTIR spectra of physical mixtures appear as the summa-
tions of the individual spectra of components indicating no
interactions between CBZ and polymers in physical mixtures. In
the spectrum of the extrudate from formulation 7, the peaks at
3465 cm−1 and 3157 cm−1 were replaced by a weak peak at
3485 cm−1 which is characteristic of CBZ form I 43. This indicates
that most CBZ (initially in form III) is transformed into an
amorphous form after HME and only a small amount is present
as crystalline form I. The sharp peak at 1678 cm−1 is broader and
shifted to 1682 cm−1 which could indicate the formation of an
intermolecular hydrogen bond between CBZ and VA64. There
was no evidence of an interaction between CBZ and EPO as the
peak at 1731 cm−1 remained unchanged.
The residual CBZ crystals in extrudates from formulation 8 were
present in both form I and form III as weak peaks at 3485 and
3466 cm−1 were observed. Four characteristic peaks at 1741, 1731,
1677 and 1643 cm−1 were replaced by three slightly broader peaks at
1735, 1683 and 1633 cm−1 reﬂecting a possible interaction among
CBZ, SOL and EPO. This interaction between drug and polymers can
facilitate miscibility and, by inhibiting the movement of molecules to
some extent, improve the physical stability of extrudates.3.5. Dissolution study
The dissolution proﬁles of pure CBZ, extrudates and correspond-
ing physical mixtures are shown in Fig. 9. In comparison to pure
CBZ, the dissolution rate of physical mixtures was slightly
increased probably because the hydrophilic polymers can wet
the surface of drug particles and act to solubilize them. The
dissolution of extrudates was markedly enhanced with total release
occurring within 20 min. This clearly shows that a remarkable
improvement in dissolution performance was achieved by HME.
3.6. Accelerated stability testing
The results of storage under accelerated stability conditions for 3
months are summarized in Table 3. Some characteristic peaks of
crystalline drug were observed to grow in the XRD proﬁles of
extrudates from formulation 7 after 1 month, indicating recrys-
tallization of amorphous drug during storage. Despite this, a
decrease in the dissolution performance did not occur. Two
possible explanations for the lack of change dissolution could be
ﬁrst, that the recrystallized CBZ crystals were small in size and
sufﬁciently dispersed within the hydrophilic polymers, and second,
that solubilization of drug due to the hydrophilic polymers
occurred as previously demonstrated in the dissolution study.
In the case of extrudates from formulation 8, no substantial
recrystallization was observed by XRD over the 3 months storage
suggesting CBZ is more stable in this formulation. This may be
because SOL can engage in more extensive hydrogen bonding
with CBZ and EPO, resulting in less molecular mobility. In
addition, there were no signiﬁcant variations in content of drug
and related substances nor in dissolution proﬁles after storage.
Taken together, these results imply that extrudates from formula-
tion 8 are stable over the storage period and that the small quantity
of CBZ microcrystals (approximately 7.7%) found after storage
has little effect on the stability of the extrudates.
3.7. Hygroscopicity
It is well documented that hygroscopicity plays an important role
in determining the stability of solid dispersions since water may
act as a plasticizer and enhance the mobility of the polymer chains
thus decreasing the Tg of amorphous substances and encouraging
Table 3 Physicochemical stability of extrudates from formulations 7 and 8 after accelerated stability testing.
Sample Condition, time (40 1C/75% RH) Appearance XRD Q5/Q20 (%) CBZ/Related substances (%)
Extrudates from formulation 7 Package, 0 month Loose powder A/C 96.3/98.3 98.6/0.42
Package, 1 month Loose powder C/A 89.9/99.8 98.8/0.51
Package, 2 months Loose powder C/A 90.5/99.8 98.4/0.52
Package, 3 months Loose powder C/A 91.0/99.2 98.2/0.53
Extrudates from formulation 8 Package, 0 month Loose powder A/C 85.2/99.8 96.7/0.40
Package, 1 month Loose powder A/C 90.9/98.8 98.2/0.42
Package, 2 months Loose powder A/C 90.1/99.9 96.6/0.50
Package, 3 months Loose powder A/C 92.4/99.2 96.4/0.49
A/C: amorphous with a small amount of microcrystals, C/A: predominantly crystalline;
Q5 and Q20: percent drug release after 5 and 20 min, respectively.
Figure 10 Moisture uptake (hygroscopicity) of CBZ, polymers and
extrudates (Ext) from formulations 1, 3, 5, 7 and 8.
Polymer combination of solid dispersions of carbamazepine 271recrystallization. EPO is less hygroscopic than either VA64 or
SOL so that hygroscopicity of extrudates should be decreased by
introducing EPO into formulations. To investigate this, the
hygroscopicity of CBZ, polymers and exrtudates was investigated
at different RH values (Fig. 10).
VA64 became transparent and SOL agglomerated when stored
at 75% RH and 92.5% RH for 7 days, while EPO and CBZ
remained dry powders at all RH consistent with their lower
hygroscopicity. It is interesting to note that the order of hygro-
scopicity of extrudates is the same as that of the polymers
indicating the hygroscopicity of an extrudate is decreased by
introducing a polymer with lower hygroscopicity such as EPO.
Although conventional plasticizers such as citrate esters44,45,
surfactants46 and low-molecular weight PEGs47 can be used to
decrease the viscosity of molten polymers, the toxicity of
plasticizers restricts their application. Combing polymers with
different Tg values may be a better choice since they not only
avoid the disadvantage of conventional plasticizers but also impart
synergistic advantages such as decreasing the hygroscopicity of
solid dispersions as demonstrated in our study.4. Conclusions
The selection of polymer and processing temperature are important
concerns in the preparation of solid dispersions containing a
thermally unstable drug by HME. Compared to single polymers,polymer combinations may beneﬁt the manufacture of amorphous
solid dispersions by improving drug-polymer miscibility and
decreasing the processing temperature. Using a high drug loading,
solid dispersions containing amorphous and microcrystalline CBZ
could be obtained by HME using SOL:EPO (1:1, w/w). These
dispersions had superior in vitro dissolution of the poorly water-
soluble drug and remained physicochemically stable for up to
3 months under accelerated stability testing conditions used for CBZ
tablets.Acknowledgments
We would like to thank the Resin Division Technical Service
Center of Evonik Industries (Shanghai, China) for providing the
extrusion equipment and Eudragit EPO. We also thank the
Technical Service Center of BASF, Shanghai, China for supplying
Kollidon VA64 and Soluplus.References
1. Singh A, Worku ZA, van den Mooter G. Oral formulation strategies to
improve solubility of poorly water-soluble drugs. Expert Opin Drug
Deliv 2011;8:1361–78.
2. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water
solubility. Adv Drug Deliv Rev 2007;59:677–94.
3. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of
active pharmaceutical ingredients to improve solubility and dissolution
rates. Adv Drug Deliv Rev 2007;59:617–30.
4. Xia D, Cui F, Piao H, Cun D, Jiang Y, Ouyang M, et al. Effect of
crystal size on the in vitro dissolution and oral absorption of
nitrendipine in rats. Pharm Res 2010;27:1965–76.
5. Hussain MD, Saxena V, Brausch JF, Talukder RM. Ibuprofen-
phospholipid solid dispersions: improved dissolution and gastric
tolerance. Int J Pharm 2012;422:290–4.
6. Patel JS, Patel RP. Preparation, characterization and in vitro dissolu-
tion study of Nitrazepam: cyclodextrin inclusion complex. J Pharm
Bioallied Sci 2012;4(Suppl):S106–7.
7. Leuner C, Dressman J. Improving drug solubility for oral delivery
using solid dispersions. Eur J Pharm Biopharm 2000;50:47–60.
8. Serajuddin AT. Solid dispersions of poorly water-soluble drugs: early
promises, subsequent problems, and recent breakthroughs. J Pharm Sci
1999;88:1058–66.
9. Zajc N, Obreza A, Bele M, Srcic S. Physical properties and dissolution
behaviour of nifedipine/mannitol solid dispersions prepared by hot
melt method. Int J Pharm 2005;291:51–8.
10. Vemavarapu C, Mollan MJ, Needham TE. Coprecipitation of pharma-
ceutical actives and their structurally related additives by the RESS
process. Powder Tech 2009;189:444–53.
J. Liu et al.27211. Badens E, Majerik V, Horváth G, Szokonya L, Bosc N, Teillaud E, et al.
Comparison of solid dispersions produced by supercritical antisolvent and
spray-freezing technologies. Int J Pharm 2009;377:25–34.
12. Inam MA, Ouattara S, Frances C. Effects of concentration of
dispersions on particle sizing during production of ﬁne particles in
wet grinding process. Powder Tech 2011;208:329–36.
13. Almeida A, Possemiers S, Boone MN, de Beer T, Quinten T, van
Hoorebeke L, et al. Ethylene vinyl acetate as matrix for oral sustained
release dosage forms produced via hot-melt extrusion. Eur J Pharm
Biopharm 2011;77:297–305.
14. Verhoeven E, de Beer TR, Schacht E, van den Mooter G, Remon JP,
Vervaet C. Inﬂuence of polyethylene glycol/polyethylene oxide on the
release characteristics of sustained-release ethylcellulose mini-matrices
produced by hot-melt extrusion: in vitro and in vivo evaluation. Eur J
Pharm Biopharm 2009;72:463–70.
15. Gryczke A, Schminke S, Maniruzzaman M, Beck J, Douroumis D.
Development and evaluation of orally disintegrating tablets (ODTs)
containing Ibuprofen granules prepared by hot melt extrusion. Colloids
Surf B 2011;86:275–84.
16. Witzleb R, Kanikanti VR, Hamann HJ, Kleinebudde P. Solid lipid
extrusion with small die diameters-electrostatic charging, taste mask-
ing and continuous production. Eur J Pharm Biopharm 2011;77:
170–7.
17. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu
SK, et al. Pharmaceutical applications of hot-melt extrusion: part I.
Drug Dev Ind Pharm 2007;33:909–26.
18. Dinunzio JC, Brough C, Hughey JR, Miller DA, Williams 3rd RO,
McGinity JW. Fusion production of solid dispersions containing a
heat-sensitive active ingredient by hot melt extrusion and Kinetisol
dispersing. Eur J Pharm Biopharm 2010;74:340–51.
19. Chokshi RJ, Shah NH, Sandhu HK, Malick AW, Zia H. Stabilization
of low glass transition temperature indomethacin formulations: impact
of polymer-type and its concentration. J Pharm Sci 2008;97:2286–98.
20. Qi S, Gryczke A, Belton P, Craig DQM. Characterization of solid
dispersions of paracetamol and EUDRAGITsE prepared by hot-melt
extrusion using thermal, microthermal and spectroscopic analysis. Int J
Pharm 2008;354:158–67.
21. Liu HJ, Wang P, Zhang XY, Shen F, Gogos CG. Effects of extrusion
process parameters on the dissolution behavior of indomethacin in
Eudragits EPO solid dispersions. Int J Pharm 2010;383:161–9.
22. Prodduturi S, Urman K, Otaigbe J, Repka M. Stabilization of hot-melt
extrusion formulations containing solid solutions using polymer
blends. AAPS Pharm Sci Tech 2007;8. Article 50.
23. Kalivoda A, Fischbach M, Kleinebudde P. Application of mixtures of
polymeric carriers for dissolution enhancement of fenoﬁbrate using
hot-melt extrusion. Int J Pharm 2012;429:58–68.
24. Sakurai A, Sakai T, Sako K, Maitani Y. Polymer combination
increased both physical stability and oral absorption of solid disper-
sions containing a low glass transit ion temperature drug: physico-
chemical characterization and in vivo study. Chem Pharm Bull
2012;60:459–64.
25. Sehic ́ S, Betz G, Hadzidedic ́ S, El-Arini SK, Leuenberger H.
Investigation of intrinsic dissolution behavior of different carbamaze-
pine samples. Int J Pharm 2010;386:77–90.
26. Liu X, Lu M, Guo Z, Huang L, Feng X, Wu C. Improving the
chemical stability of amorphous solid dispersion with cocrystal
technique by hot melt extrusion. Pharm Res 2012;29:806–17.
27. Hoftyzer PJ, Krevelen DWV. Properties of polymers. Amsterdam:
Elsevier; 1976.
28. Zheng JM. Polymer science in pharmaceutics. Beijing: Chinese
Medical Science Press; 2000.
29. Foster A, Hempenstall J, Tucker I, Rades T. Selection of excipients for
melt extrusion with two poorly water soluble drugs by solubility
parameter calculation and thermal analysis. Int J Pharm
2001;226:147–61.30. Chokshi RJ, Sandhu HK, Iyer RM, Shah NH, Malick AW, Zia H.
Characterization of physico-mechanical properties of indomethacin
and polymers to assess their suitability for hot-melt extrusion process
as a means to manufacture solid dispersion/solution. J Pharm Sci
2005;94:2463–74.
31. Flicker F, Eberle VA, Betz G. Variability in commercial carbamaze-
pine samples-impact on drug release. Int J Pharm 2011;410:99–106.
32. Fu J, Xu L, Wang X, Zhang S, Tao X, Zhao X, et al. Nimodipine
(NM) tablets with high dissolution containing NM solid dispersions
prepared by hot-melt extrusion. Drug Dev Ind Pharm 2011;37:934–44.
33. Tian Y, Booth J, Meehan E, Jones DS, Li S, Andrews GP.
Construction of drug-polymer thermodynamic phase diagrams using
Flory-Huggins interaction theory: identifying the relevance of tem-
perature and drug weight fraction to phase separation within solid
dispersions. Mol Pharm 2013;10:236–48.
34. The State Pharmacopoeia Committee of China. The pharmacopoeia of
the People's Republic of China. Beijing: Chinese Medicine Science
and Technology Press; 2010.
35. Greenlagh DJ, Williams AC, Timmins P, York P. Solubility para-
meters as predictors of miscibility in solid dispersions. J Pharm Sci
1999;88:1182–90.
36. Patterson JE, James MB, Forster AH, Lancaster RW, Butler JM, Rades
T. Preparation of glass solutions of three poorly water soluble drugs by
spray drying, melt extrusion and ball milling. Int J Pharm
2007;336:22–34.
37. Sathigari SK, Radhakrishnan VK, Davis VA, Parsons DL, Babu RJ.
Amorphous-state characterization of efavirenz—polymer hot-melt
extrusion systems for dissolution enhancement. J Pharm Sci
2012;101:3456–64.
38. Hughey JR, Keen JM, Brough C, Saeger S, McGinity JW. Thermal
processing of a poorly water-soluble drug substance exhibiting a high
melting point: the utility of KinetiSols dispersing. Int J Pharm
2011;419:222–30.
39. Suzuki H, Sunada H. Comparison of nicotinamide, ethylurea and
polyethylene glycol as carriers for nifedipine solid dispersion systems.
Chem Pharm Bull 1997;45:1688–93.
40. Grzesiak AL, Lang M, Kim K, Matzger AJ. Comparison of the four
anhydrous polymorphs of carbamazepine and the crystal structure of
form I. J Pharm Sci 2003;92:2260–71.
41. Munson EJ. Analytical techniques in solid-state characterization. In:
Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR, editors. Developing
solid oral dosage forms: pharmaceutical theory and practice. 1st ed.
Oxford: Elsevier; 2009. p. 61–74.
42. Thomas S, Mathela CS, Agarwal A, Paul SK. Identiﬁcation and
structural elucidation of an unknown impurity in carbamazepine active
pharmaceutical ingredient by liquid chromatography-tandem mass
spectrometry and semi-preparative chromatographic isolation. J Pharm
Biomed Anal 2011;56:423–8.
43. Rustichelli C, Gamberini G, Ferioli V, Gamberini MC, Ficarra R,
Tommasini S. Solid-state study of polymorphic drugs:carbamazepine.
J Pharm Biomed 2000;23:41–54.
44. Repka MA, Gerding TG, Repka SL, McGinity JW. Inﬂuence of
plasticizers and drugs on the physical-mechanical properties of
hydroxypropylcellulose ﬁlms prepared by hot melt extrusion. Drug
Dev Ind Pharm 1999;25:625–33.
45. Aitken-Nichol C, Zhang F, McGinity JW. Hot melt extrusion of
acrylic ﬁlms. Pharm Res 1996;13:804–8.
46. Ghebremeskel AN, Vemavarapu C, Lodaya M. Use of surfactants as
plasticizers in preparing solid dispersions of poorly soluble API:
stability testing of selected solid dispersions. Pharm Res
2006;23:1928–36.
47. Follonier N, Doelker E, Cole ET. Evaluation of hot-melt extrusion as a
new technique for the production of polymer-based pellets for
sustained release capsules containing high loadings of freely soluble
drugs. Drug Dev Ind Pharm 1994;20:1323–39.
